Showing results (1451-1460 of 2,321) with videos related to
Sort By:
Pageof 233
Environmental Science & Technology|May 1, 2012
Quantitative separation of monomeric U(IV) from UO2 in products of U(VI) reductionDaniel S Alessi, Benjamin Uster, Harish Veeramani, et al.Journal of Medicinal Chemistry|April 3, 1992
Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxidesJ W Ellinboe, T R Alessi, T M Dolak, et al.Circulation|March 17, 2004
Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) studyP E Morange, C Simon, M C Alessi, et al.The Journal of Biological Chemistry|January 6, 2005
Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell typesBettina A Dümmler, Camilla Hauge, Joachim Silber, et al.Journal of Hypertension|September 7, 2017
Disruption of the with no lysine kinase-STE20-proline alanine-rich kinase pathway reduces the hypertension induced by angiotensin IILuz G Cervantes-Perez, Maria Castaneda-Bueno, Jose V Jimenez, et al.Journal of Thrombosis and Haemostasis : JTH|July 17, 2008
Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrateC Négrier, C Rothschild, J Goudemand, et al.The Biochemical Journal|September 11, 2009
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's diseaseR Jeremy Nichols, Nicolas Dzamko, Jessica E Hutti, et al.Journal of Clinical Laboratory Analysis|July 16, 2008
Validation of fecal elastase-1 determination using immunoenzymatic assay in HIV-infected patientsClaudia Giorgia Bronzatti de Oliveira, Fernando Luiz Affonso Fonseca, Nicolle Stackunas Salotto, et al.Journal of Thrombosis and Haemostasis : JTH|July 28, 2019
Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndromeMarc Laine, Vassili Panagides, Corinne Frère, et al.Journal for Immunotherapy of Cancer|March 27, 2021
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)Biagio Ricciuti, Greg Jones, Mariano Severgnini, et al.Pageof 233